69076-29-5

Basic information

• Product Name: methyl 4-(3-chloropropoxy)benzoate
• Synonyms: methyl 4-(3-chloropropoxy)benzoate
• CAS NO: 69076-29-5
• Molecular Weight: 228.675
• Mol File: 69076-29-5.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: methyl 4-(3-chloropropoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-(3-chloropropoxy)benzoate(69076-29-5)
• EPA Substance Registry System: methyl 4-(3-chloropropoxy)benzoate(69076-29-5)

Safety Data

• Hazardous Substances Data: 69076-29-5(Hazardous Substances Data)

Upstream product

• 142-28-9 1,3-Dichloropropane 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 109-70-6 1.3-chlorobromopropane 

Downstream Products

• 117023-68-4 4-[3-[4-[Hydroxy(diphenyl)methyl]-1-piperidinyl]propoxy]benzoic acid methyl ester 
• 163210-57-9 methyl 4-[3-(1-Imidazolyl)propyloxy]benzoate 
• 464898-19-9 (4-(3-(piperidin-1-yl)propoxy)phenyl)methanol 
• 437651-42-8 methyl 4-[3-(dibutylamino)propoxyl]benzoate 
• 141626-36-0 dronedarone 
• 1334335-21-5 C₁₇H₂₄N₂O₂ 
• 752202-08-7 4-[3-(1-piperidinyl)propyloxy]benzoyl chloride 
• 767286-87-3 4-(3-(piperidin-1-yl)propoxy)benzoic acid 
• 111626-39-2 4-[3-[4-[Bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]benzoic acid ethyl ester hydrochloride 
• 124063-04-3 Methyl 4-[3-[N-(1,4-benzodioxan-6-yl)amino]propoxy]benzoate 
• 117023-67-3 4-<3-<4--1-piperidinyl>propoxy>benzoic acid methyl ester (E)-2-butenedioate (1:1) 
• 111627-11-3 4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]benzoic acid 
• 117023-66-2 4-<3-<4--1-piperidinyl>propoxy>benzoic acid methyl ester 

Relevant articles and documents

A nitric oxide donor nature of the benzofuran compounds (by machine translation)

The invention discloses a benzofuran compound with nitrous oxide donor property. The benzofuran compound is a compound shown by a general formula (I) or a pharmaceutically acceptable salt thereof, wherein in the formula, R1 or R2 represents independent hy

Process for preparing dronedarone

The present invention relates to a process for preparing dronedarone and in particular for preparing an intermediate useful in the preparation of dronedarone. Furthermore, the present invention relates to a process for preparing crystalline dronedarone hydrochloride as well as pharmaceutical compositions comprising this salt.

NPY ANTAGONISTS, PREPARATION AND USES

The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.